Vascular endothelial growth factor (VEGF) is a potent stimulator for angiogenesis. It has been implicated in growth and metastasis of thyroid cancer. Three functional single nucleotide polymorphisms (SNPs) of VEGF (K2578C/A, K634G/C, and C936C/T) are known to be related with VEGF expression. We conducted a case-control study to evaluate the genetic effects of these three functional SNPs on the development of thyroid cancer and lymph node metastasis. A total of 332 cases and 261 controls were recruited for this study. The genotypes were determined by the TaqMan 5 0 -nuclease assay. Hardy-Weinberg equilibrium (HWE) was tested for each SNP, and genetic effects were evaluated by the c 2 -test and multiple logistic regression. We used Bonferroni correction to account for multiple testing, and a two-tailed P value !0 . 017 was considered statistically significant. All three SNPs were in HWE. The A allele of K2578C/A (i.e. SNP rs699947) increased a risk for thyroid cancer (adjusted ORZ136, 95% CIZ1 . 02-1 . 81, PZ0 . 039).
Introduction
Thyroid cancer accounts for !1% of all human cancers but is the most common endocrine neoplasia (Schlumberger & Torlantano 2000) . The incidence of thyroid cancer (0 . 5-10/ 100 000) increases with age, and it reaches a plateau after the age of 50 years (DeLellis et al. 2004) . Thyroid cancer is two to four times more frequent in females than males. Radiation exposure, hormonal factors, and family history are the risk factors for thyroid carcinoma (Kondo et al. 2006) . Genetic predisposition has been proposed as one of the risk factors for thyroid cancer (Malchoff & Malchoff 2006) . Different histological types of thyroid cancer have distinct clinical features. More than 90% thyroid tumors are well-differentiated carcinoma, including papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). For these two types of thyroid cancer, the treatment can be effective and prognosis is often favorable for patients identified in the early stage.
In contrast, anaplastic thyroid cancer is aggressive, responds poorly to treatment, and is associated with worse prognosis (Kondo et al. 2006) . Follicular thyroid carcinoma tends to spread via the blood stream, whereas papillary thyroid tumor spreads occur via the lymphatic system (Turner et al. 2003) .
Angiogenesis is a process of new blood vessel development from preexisting vasculature. The vascular endothelial growth factor (VEGF) is one of the most potent endothelial cell mitogens and plays a crucial role in both angiogenesis and lymphogenesis (Carmeliet & Jain 2000) . The microvascular density is increased in the thyroid malignancy compared with normal thyroid tissue and benign thyroid tumors (Segal et al. 1996 , Akslen & Livolsi 2000 . Growing evidence from in vitro and in vivo experiments have shown that increased VEGF expression promotes thyroid cancer cell growth, subsequent lymph node metastasis, local invasion, and distant metastasis, whereas the inhibition of VEGF signaling results in suppression of the tumor growth (Lin & Chao 2005) .
A previous study reported that plasma VEGF levels in advanced thyroid cancer patients were significantly elevated (Lin et al. 2003) . A 5-year cohort study showed that expression of VEGF was strongly associated with a higher frequency of local and distant recurrence of papillary thyroid carcinoma (Kilicarslan et al. 2003) .
Some polymorphisms in the promoter and 3 0 -untranslated region are known to regulate VEGF expression (Brogan et al. 1999 , Awata et al. 2002 . Three single nucleotide polymorphisms (SNPs; K2578C/A, K634G/C in the promoter region and C936C/T in the 3 0 -untranslated region) are common in the Han Chinese population (http://www.ncbi. nlm.nih.gov/SNP/) and are related to VEGF protein production (Rogers & D'Amato 2006) . The current SNP nomenclature for the above three SNPs is rs699947 for K2578C/A, rs2010963 for K634G/C, and rs3025039 for C936C/T. VEGF polymorphisms have been implicated in the susceptibility to several cancers including prostate cancer (Sfar et al. 2006) , breast cancer (Kataoka et al. 2006) , lung cancer (Koukourakis et al. 2004) , gastric cancer (Tzanakis et al. 2006) , and renal cell carcinoma (Kawai et al. 2007) . However, the effect of these polymorphisms on thyroid cancer has not been reported. On the basis of the biological and pathologic significance of VEGF, it is possible that functional genetic variations in the VEGF gene may contribute to the development and progression of thyroid cancer. To test the hypothesis, we conducted a case-control study to evaluate the effects of these three functional polymorphisms on the development of thyroid cancer and lymph node metastasis.
Materials and Methods

Subjects
We initially recruited 332 patients with thyroid cancer (only PTC or FTC was enrolled) and 261 controls at the Kaohsiung Medical University Memorial Hospital in Taiwan. The initial diagnostic year of thyroid cancer was from 1980 to 2006. The diagnosis with thyroid cancer and lymph node metastasis were both confirmed by pathological examination. The presence of regional lymph node metastasis was detected while the patient receiving thyroidectomy. The control subjects were patients from the Department of Endocrinology and Otorhinolaryngology for other reasons. None of the controls had known thyroid disease or any type of cancer upon enrollment. All of the control subjects received thyroid physical examination by an endocrinologist or otolarygologists. Twenty-one control subjects with simple goiter have been further evaluated by thyroid sonography and fine needle aspiration to exclude any malignant change. The female versus male ratio was higher in the cases than controls. To reduce the impact of unbalanced sex ratio in this case-control study, we subsequently enrolled another 156 female controls and genotyped the 'interesting' SNP based on the results from the initial study subjects. These 156 female controls were recruited from the healthy individuals who came to the Department of Preventive Medicine for annual health checkup. None of them had reported cancer or thyroid disease. Information on demographic characteristics, family history of cancer, and exposure to ionizing radiation were collected. The study was proved by the Institutional Review Board of Kaohsiung Medical University Hospital and written informed consent was given by each subject or custodian (if the age of the participant was !18 years old).
Genotyping
Genomic DNA was extracted from peripheral blood by a standard method. Genotyping was carried out by the TaqMan technology. Briefly, PCR primers and TaqMan minor groove binder probes were designed and reactions were performed in 96-well microplates with ABI 9700 thermal cyclers (Applied Biosystems, Foster City, CA, USA). The information about probe sequences and PCR can be found in Supplementary  Table 1 which can be viewed online at http://joe. endocrinology-journals.org/content/vol195/issue2/. Fluorescence was measured with an ABI 7500 Real-Time PCR System and analyzed with its System SDS software version 1.2.3.
Statistical analysis
SPSS for Windows 13.0 version was used for statistical analysis. Continuous variables were analyzed by independent t-test and were presented as meanGS.D. Allele frequencies were estimated by direct gene counting. Observed numbers of each genotype were compared with those expected for Hardy-Weinberg equilibrium (HWE) using the c 2 -test. Genetic effects were first assessed by c 2 -test or Fisher's exact test. Multiple logistic regression analysis was performed to adjust for the effects of age and sex while assessing the genetic effects. A trend test (P trend ) assuming a dose-response with increasing number of a risk allele was also performed. Haploview was applied to calculate linkage disequilibrium (LD) and haplotype blocks. Haplotype analysis was conducted using the Haclustering program (Tzeng et al. 2006) . We used Bonferroni correction to account for multiple testing, and a two-tailed P value !0 . 017 (Z0 . 05/3 SNPs) was considered statistically significant. Table 1 shows the baseline characteristics of the subjects. The genotyping call rate for each SNP ranged from 88 to 92%. The age of study group ranged from 11 to 82 years old. No significant difference of age was found between the case and control groups. Females were predominant among our cases (P!0 . 001), which is in agreement with the gender distribution in patients with thyroid cancer. Histological were adjusted for and an additive mode of inheritance was assumed. We also found that the frequency for either the AC or AA genotype was highest in patients with lymph node metastasis, followed by patients without lymph node metastasis, and lowest in controls. The proportion of the A allele carriers from these three types of subjects yielded a trend test P value of 0 . 019 (57 . 1 vs 45 . 0 vs 40 . 5%), which was close to Bonferroniadjusted significance. When we analyzed each type of thyroid cancer, the results were less significant but the pattern of association was still present (Supplementary Tables 2 and 3 which can be viewed online at http://joe.endocrinologyjournals.org/content/vol195/issue2/). For SNPs rs2010963 and rs3025039, we did not find any significant association between genotypes and phenotypes under dominant, recessive, or additive genetic model. When these two SNPs were analyzed for the patients with lymph nodes metastasis, neither of them reached to the statistical significance.
Results
The sex distribution was very different between cases and controls. We genotyped SNP rs699947 in additional 156 female controls and found that the A allele frequency in the control increased from the original 23 . 3 to 24 . 7%. These controls did not change the potential effect of SNP rs699947. We further divided the original study subjects by sex and examined the sexspecific genetic effect (Table 3) . We found that the association between SNP rs699947 and the risk of thyroid cancer existed only in men (adjusted ORZ1 . 97, 95% CIZ1 . . 37 
Discussion
In the present study, we examined the relationship between three functional SNPs of the VEGF gene and the risk of thyroid cancer and regional lymph node involvement. Our results suggest a potential role of the VEGF promoter SNP rs699947 (i.e. K2578 C/A) in the development of thyroid cancer and lymph node metastasis. The A allele of SNP rs699947 increases a risk for thyroid cancer development, and may also facilitate lymph node metastasis. The effect of this risk allele is present in men but not in women. The association between genetic variation in VEGF and thyroid cancer is biologically plausible for several reasons: first, VEGF has been identified as a critical factor in angiogenesis required for tumor growth (Bunone et al. 1999) . Second, VEGF expression has been related to tumor progression (Viglietto et al. 1995 , Lewy-Trenda & Wierzchniewska-Lawska 2002 and metastasis (Fellmer et al. 1999 , Klein et al. 1999 . The promoter polymorphism of the VEGF gene in our study in part explains the variation of individual susceptibility to thyroid cancer and regional lymph node involvement. However, our positive result is based on a small number of male subjects. Further studies to replicate our result are necessary. Before any further replication, our result should be considered potentially intriguing but tentative.
It is of particular interest that the genetic risk of rs699947 only exists in males. Although the prevalence of thyroid cancer in women is in excess of men, being male is regarded as one of the high risk factors for thyroid cancer recurrence and cancer death (Liska et al. 2005) . A growing body of evidence suggests that sex hormone plays a role in regulating VEGF expression. Studies showed that androgens can stimulate VEGF expression (Haggstrom et al. 1999 , Stewart et al. 2001 , Woodward et al. 2005 . Androgens can activate hypoxia inducible factor-1 (Mabjeesh et al. 2003) which in turn translocates into nucleus to enhance VEGF expression (Josko & Mazurek 2004) . On the other hand, studies also demonstrate that both estrogen and progestin can increase VEGF expression. Garvin et al. (2005) showed that estrogen acts as an angiogenic switch in breast cancer cells. Furthermore, progesterone-response elements had been identified in the promoter of the VEGF gene (Mueller et al. 2003) . Mutation in the Sp-1 region of VEGF promoter can abolish progestin induction of VEGF synthesis (Wu et al. 2005) . The role of sex hormone in regulation of VEGF expression in thyroid cancer has not been explored and our finding of sex-specific VEGF genetic effect has yet to be replicated by other studies.
Twenty-nine cases with genotypes at SNP rs699947 do not have information regarding lymph node metastasis. If all these 29 cases have a systemic bias towards the group with lymph node metastasis, the result is still significant after adding all of them into statistical models. On the other hand, if the systemic bias is towards the group without lymph node metastasis, the statistical result remains significant. For the patients without evidence of lymph node metastasis, it is possible that the surgeons did not remove the involved lymph nodes leading to an underestimation of the percentage of lymph node metastasis. However, this bias would be independent of genotypes and should not result in a different conclusion. Retrospectively recruiting post-operative patients could lead to survival bias. To test for this potential bias and its impact on our conclusion, we divided the subjects into two groups by the follow-up period R5 and !5 years. We found that the frequency of the risk A allele of SNP rs699947 was 28 . 0% in the long follow-up group and 28 . 5% in the short follow-up group. Therefore, the ascertainment of this retrospective case-control study did not have survival bias.
In conclusion, we found that the K2578 C/A SNP in the promoter region of the VEGF gene may predispose the risk of development of thyroid cancer and regional lymph node metastasis. Our data also suggested a sex-specific effect and males are under stronger genetic influence than females. 
